Table of Contents
- Clinical trials overview
- Blood cancers studied in Ibrutinib trials
- Treatment combinations and study designs
- Main endpoints measured in the trials
- Who can participate
- Special patient groups
- Long-term access and extension studies
Clinical trials overview
The trial data show that Ibrutinib is being studied in many interventional trials, which means patients receive a planned treatment and the results are measured.[1] The studies include Phase 1, Phase 2, Phase 3, Phase 3b, and Phase 4 trials, so the research covers early safety work and later comparison studies.[1] Several trials are authorised, some are completed, and one listed study was withdrawn.[1]
Many studies compare Ibrutinib with other active treatments, while others test it as part of a combination or as long-term follow-up after earlier treatment.[1] The main goal across the trials is to learn how well treatment works and how safe it is in different patient groups.[1]
Blood cancers studied in Ibrutinib trials
Most trials focus on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).[2] Some of the largest studies compare Ibrutinib-based treatment with other first-line options in previously untreated CLL or CLL/SLL.[2][3]
Other trials study Ibrutinib in mantle cell lymphoma (MCL), including untreated, relapsed/refractory, and older patient groups.[4][5] There are also studies in Waldenström’s macroglobulinemia, follicular lymphoma, marginal zone lymphoma, and diffuse large B-cell lymphoma.[6][7][8]
Some trials go beyond cancer and study Ibrutinib in chronic graft-versus-host disease (cGVHD), which is a condition that can happen after a transplant when the donor’s cells attack the patient’s body.[9] One trial also studies Ibrutinib for autoimmune hemolytic anemia in people with CLL/SLL or CLL-like monoclonal B-cell lymphocytosis.[10]
Treatment combinations and study designs
Some studies test Ibrutinib alone, while others combine it with drugs such as venetoclax, rituximab, or obinutuzumab.[2][3][6]
In the CLL17 study, the trial compares continuous Ibrutinib alone with fixed-duration venetoclax plus obinutuzumab and fixed-duration venetoclax plus Ibrutinib.[2] In the TAILOR study, researchers are testing tailored Ibrutinib treatment regimens and comparing them with historical controls, which means older trial results used as a comparison group.[3]
In mantle cell lymphoma, some trials compare Ibrutinib plus rituximab with chemotherapy-based treatment, while others test Ibrutinib with venetoclax and rituximab.[4][6] Another Phase 4 study in older patients compares rituximab/Ibrutinib with rituximab/chemotherapy.[11]
A few studies use Ibrutinib in more complex treatment plans, such as CAR-T-cell trials or basket studies, where one study includes several related patient groups or diseases.[5][12]
Main endpoints measured in the trials
The most common endpoint is progression-free survival (PFS), which measures how long patients live without the disease getting worse.[2][4][6]
Many studies also measure overall response rate (ORR), which is the share of patients whose disease shrinks or disappears by the study rules.[3][8][13] Some trials look at complete response (CR), very good partial response (VGPR), or complete remission, which means the disease is not found or is much smaller after treatment.[6][6][11]
Several trials use minimal residual disease (MRD) as an endpoint. MRD means a very small amount of disease that can remain after treatment and needs very sensitive tests to detect it.[3][14]
Safety is also important, especially in early-phase studies. These trials measure dose-limiting toxicities, adverse events, laboratory changes, vital signs, and ECG changes, which are checks on heart rhythm and electrical activity.[5][9]
Who can participate
Eligibility depends on the trial and the disease stage.[1] Some studies include previously untreated patients, meaning they have not had treatment for that disease before.[2][6]
Other studies include relapsed or refractory patients, meaning the disease returned after treatment or did not respond well to earlier therapy.[4][8] Some studies also ask for patients with specific risk features, such as high-risk markers, TP53 changes, or a certain International Prognostic Index score.[4][15][16]
One study includes physically fit patients with creatinine clearance of at least 30 ml/min, which is a measure of kidney function.[14] Another trial focuses on pediatric patients, including children from age 1 to under 22 years with cGVHD.[9]
Special patient groups
Some trials focus on patients with special disease features, such as TP53 aberrations, which means changes in a gene linked with treatment resistance and disease behavior.[15] One study follows the size of TP53-mutated subclones over time, which helps researchers see how the cancer cell population changes during treatment.[15]
Other studies focus on people who are not in complete remission or who still have detectable MRD after treatment.[16] In the NEXT STEP trial, Ibrutinib and obinutuzumab are being used to try to convert these patients to MRD-negative complete remission.[16]
There are also studies in older patients with untreated mantle cell lymphoma, where the goal is to see whether rituximab/Ibrutinib performs better than rituximab/chemotherapy.[11] This shows that the research includes both newly diagnosed and more vulnerable patient groups.[11]
Long-term access and extension studies
Some trials are not designed to start a new treatment strategy but to give continued access to Ibrutinib for patients who were already benefiting from it.[17][18] These extension studies also collect long-term safety and efficacy data, which means they track how well treatment keeps working and what side effects or other problems appear over time.[17]
One long-term protocol includes many disease groups, such as follicular lymphoma, CLL, Waldenström macroglobulinemia, multiple myeloma, marginal zone lymphoma, diffuse large B-cell lymphoma, urothelial carcinoma, breast cancer, acute myeloid leukemia, graft-versus-host disease, and mantle cell lymphoma.[18] This shows that Ibrutinib is being followed in a broad range of ongoing study settings, not only in one disease.[18]
References in this article are based on the trial records listed below.
